Treatments
Programme
Results
Experts
Resources
Medications

Ozempic for weight loss, explained

Ozempic is usually prescribed as a type 2 diabetes treatment. But its active ingredient semaglutide promotes weight loss by helping you feel fuller for longer.

It’s known for its effects on weight, but Ozempic isn’t actually licensed for weight loss. Rather, it was developed as a treatment for type 2 diabetes.

So, what’s the deal—how is Ozempic used for weight loss? Here’s what to know.

iconPublished 9th October 2025

What is Ozempic?

Ozempic is a type of medicine called a GLP-1 receptor agonist. That means it works by acting like GLP-1, a natural hunger hormone. Yet Ozempic is a brand name for the active ingredient semaglutide.

Semaglutide is sold as Ozempic when it’s used to treat type 2 diabetes and Wegovy when it’s used for weight loss (though Ozempic is sometimes prescribed off-label for weight loss).

Because Ozempic hit the market first, it’s the name that’s become associated with GLP-1 weight loss medicines. And in recent years, these have surged in popularity.

Ozempic for weight loss

Okay, so how does Ozempic drive weight loss? Well, it makes you feel full and keeps your appetite at bay, so you eat less.

In clinical studies, people taking semaglutide for 68 weeks (alongside healthy lifestyle changes) lost around 17.5% of their starting weight on average — but this was with the higher 2.4mg dose, available under the Wegovy brand, not Ozempic.

The highest available dose of Ozempic is 2mg, which is licensed for type 2 diabetes, not weight loss. In trials, this 2mg dose led to an average weight loss of about 14lb (6.4kg) over 40 weeks.

More recently, studies on an even higher 7.2mg semaglutide dose (Wegovy brand) have shown up to 20.7% average weight loss, suggesting the next generation of treatment could be even more effective once approved.

FYI: Wegovy weight loss injections are available in 2.4mg. And the newer 7.2mg dose will likely be available soon.

Ozempic availability in the UK

Because it’s licensed for type 2 diabetes, Ozempic isn’t available on the NHS as a weight loss treatment.

But you can get it via private prescription, from private clinics and registered online pharmacies. Prices vary between providers.

Ozempic and the NHS

So you can’t get Ozempic on the NHS for weight loss. But you may be eligible for Wegovy if:

  • Your BMI is at least 35 or as low as 27.5 depending on:
    • Your ethnic background
    • If you meet other criteria for treatment by a specialist weight management service
  • You have at least one other health problem related to your weight

Ozempic vs other weight loss medications

Here’s how Ozempic stacks up against other weight loss medications.

Features
Active ingredient
How it’s taken
Weight loss results*
Availability
Wegovy/Ozempic
Semaglutide
Weekly injection
17.5% after 72 weeks
NHS (Wegovy), private prescription
Orlistat
Orlistat
Tablet three times per day
About 1 in 5 people lose at least 10% after a year
NHS, private prescription
Mounjaro
Tirzepatide
Weekly injection
22.5% after 72 weeks
NHS, private prescription
Retatrutide
Retatrutide
Weekly injection
24.2% in 48 weeks
Not approved yet

*Average percentage of starting weight lost in clinical trials

Mounjaro vs Ozempic

The main difference between these two is how they work: Ozempic works by acting on GLP-1 and Mounjaro works by acting on GLP-1 and another hormone called GIP.

Wegovy vs Ozempic

Wegovy and Ozempic are two names for the same medicine, but they’re distinct products. They’re approved for separate uses and come in different dose.

Discover Wegovy
Struggling to reach your target weight? You’re not alone. Find out about how medications like Wegovy can boost your efforts and get you closer to your health goals.
icon
Science backed programme
icon
Personalised support
icon
Trusted by 100,000 UK customers

Retatrutide vs Ozempic

Retatrutide isn’t approved yet, so a clinician can’t prescribe it to you. But it’s different from Ozempic in how it works: retatrutide acts like three hormones (GLP-1, GIP, glucagon) compared to one (GLP-1).

BMI requirements for Ozempic in the UK

We’ve mentioned the BMI requirements for getting semaglutide on the NHS. But what about private prescriptions?

Because Wegovy is licensed for weight management, private providers typically prescribe Wegovy rather than Ozempic for weight loss. Ozempic will only be prescribed for weight loss in specific circumstances after an individual assessment by a prescriber. This is known as off-label prescribing (using a licensed medicine for a different indication, dose, or group of patients).

Registered and qualified private providers (like us) follow similar professional standards to the NHS, but eligibility criteria can differ. Most private clinics offer treatment to people with a BMI of 30 or higher, or 27 or higher if they have a weight-related health condition or are from certain ethnic backgrounds.

Side effects of Ozempic

Ozempic side effects are fairly common, but are usually nothing to worry about and clear on their own. They include:

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation

Is Ozempic right for you?

Your provider might recommend weight loss medication if you’ve tried to lose weight another way but didn’t see the results you wanted.

Plus, semaglutide may also have other benefits for people with heart disease, PCOS or addiction.

But Ozempic isn’t recommended for:

  • People who are pregnant or breastfeeding
  • Those with a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2

It’s super important to get your prescription from a qualified medical professional. They will consider your health and medical history when deciding whether semaglutide is right for you.

Your weight loss journey

You can take the next step in your weight loss journey right now. Through our weight loss programme, you’ll get monthly weight loss medication posted to you plus guidance on how to transform your lifestyle. By the way: as well as injections, we also offer orlistat weight loss pills.

Take our quiz to see if you’re eligible. It takes less than five minutes.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
FAQ

FAQs about Ozempic

Dr Earim Chaudry, MBBS
DisclaimerAt Voy, we ensure that everything you read in our blog is medically reviewed and approved. However, the information provided is not meant to replace professional medical advice, diagnosis, or treatment. It should not be relied upon for specific medical advice.
References
icon¹

Aronne, Louis J, et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomised Clinical Trial.” JAMA,scribble-underline vol. 331, no. 1, 2024:38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936.

icon²

Electronic Medicines Compendium. “Ozempic: Information for the Patient.” Medicines.org.uk,scribble-underline 2025 https://www.medicines.org.uk/emc/files/pil.9748.pdf Accessed 3 Oct. 2025.

icon³

Eli Lilly and Company. “Lilly’s SURMOUNT-1 Results Published in The New England Journal of Medicinescribble-underline Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss in Adults with Obesity or Overweight.” Eli Lilly and Company Investor Relationsscribble-underline, 2022, https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine. Accessed 9 Oct. 2025.

icon

Food and Drug Administration. “Orlitstat - Full Prescribing Information.” FDAscribble-underline, 2022 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf Accessed 3 Oct. 2025.

icon

Food and Drug Administration. “Saxenda - Full Prescribing Information.” FDAscribble-underline, 2023 https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf Accessed 3 Oct. 2025.

icon

James, Davy. “STEP UP Trial Shows Higher Dose of Wegovy Produces Significant Weight Loss in Adults With Obesity Without Diabetes.” Applied Clinical Trialsscribble-underline, 25 June 2025, https://www.appliedclinicaltrialsonline.com/view/wegovy-weight-loss-obesity-diabetes. Accessed 9 Oct. 2025.

icon

Jastreboff, Ania M, et al. “Triple-hormone-receptor Agonist Retatrutide for Obesity—a Phase 2 Trial,” The New England Journal of Medicinescribble-underline, vol. 389, no. 6 2023:514-526 https://www.nejm.org/doi/full/10.1056/NEJMoa2301972.

icon

National Health Service. “Obesity - treatment.” NHS.ukscribble-underline, 2023 https://www.nhs.uk/conditions/obesity/treatment/ Accessed 3 Oct. 2025.

icon

National Institute for Health and Care Excellence. “Semaglutide for Managing Overweight and Obesity.” NICE.org.ukscribble-underline, 2023 https://www.nice.org.uk/guidance/ta875/resources/semaglutide-for-managing-overweight-and-obesity-pdf-82613674831813. Accessed 3 Oct. 2025.

icon¹⁰

Novo Nordisk. “Ozempic: important safety information.” Ozempic.com,scribble-underline https://www.ozempic.com/important-safety-information.html. Accessed 3 Oct. 2025.

icon¹¹

Rodriguez, Patricia J, et al. “Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity,” JAMA Internal Medicinescribble-underline, vol. 184, no. 9, 2024:1056-1064 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080.

icon¹²

“Weight Results | Ozempic (semaglutide) Injection 0.5 mg, 1 mg, or 2 mg.” NovoMedLinkscribble-underline, Novo Nordisk, https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-and-weight.html. Accessed 9 Oct. 2025.

icon¹³

Wilding, John P.H., et al. “Once-weekly semaglutide in adults with overweight or obesity.” The New England Journal of Medicinescribble-underline, vol. 384, no. 11, 2021:989-1002 https://www.nejm.org/doi/full/10.1056/NEJMoa2032183.